Currently Viewing:
Newsroom
Currently Reading
Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease
November 20, 2018 – Laura Joszt
CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma
November 15, 2018 – David Bai, PharmD
Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers
November 13, 2018 – Laura Joszt
Antiviral Therapy Prevents HCV in Patients Receiving Infected Donor Hearts
November 09, 2018 – Jaime Rosenberg
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 07, 2018 – Laura Joszt
ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens
November 06, 2018 – David Bai, PharmD
Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types
November 02, 2018 – Laura Joszt
Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma
October 31, 2018 – Mary Caffrey
The Evolution of CLL Testing and Treatment Over the Past Decade
October 30, 2018 – Laura Joszt

Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease

Laura Joszt
A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.
A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.

The findings of the phase 2/3 multicenter, multicycle clinical trial will be presented December 3 at the 60th American Society of Hematology Annual Meeting and Exposition.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) has a low overall survival of approximately just 8 to 14 months from the time of diagnosis. Patients in the trial who were treated with tagraxofusp had an overall response rate of 90%. The novel targeted therapy is directed at CD-123, an interleukein-3 receptor-α.

In stage 1 of the study, first-line and relapsed/refractory patients with BPDCN received the therapy as an intravenous infusion at 7, 9, or 12 mcg/kg on days 1 to 5 of a 21-day cycle. Stage 2 was an expansion of the trial and enrolled both first-line and relapsed/refractory patients to be treated with a 12 mcg/kg dose. Stage 3 was a pivotal trial that enrolled only first-line patients.

A total of 32 patients were enrolled in stages 1 and 2 and an additional 13 were enrolled in stage 3. Patients continued to be enrolled for the next stage of the trial, which ensured ongoing access to tagraxofusp. The median follow-up for all first-line patients treated with the 12 mcg/kg dose was 13.8 months.

The most common treatment-related adverse events (TRAEs) at the 12 mcg/kg dose were transaminitis, which indicates unusually high levels of transaminase enzymes (44%); hypoalbuminemia, or an abnormally low level of the albumin protein in the blood (44%); and thrombocytopenia, which is low blood platelet count (26%). The most serious TRAE was capillary leak syndrome, which occurred in 17% of all patients enrolled, and 0.7% of cases across all indications at the 12 mcg/kg dose and 1.6% of cases across all doses resulted in death.

“These findings give us hope for patients who have had no treatments specific to this disorder,” Naveen Pemmaraju, MD, associated professor of leukemia at The University of Texas MD Anderson Cancer Center, and lead author of the study, said in a statement.

Tagraxofusp received Breakthrough Therapy Designation for the treatment of patients with BPDCN and it has a rolling biologic license application with the FDA. It is also being investigated in other trials for patients with chronic myelomonocytic leukemia and myelofibrosis.

Reference

Pemmaraju N, Lane AA, Sweet KL, et al. Results of pivotal phase 2 clinical trial of tagraxofusp (SL-401) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Presented at: 60th American Society of Hematology Annual Meeting and Exposition; December 3, 2018; San Diego, CA. Abstract 756.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up